Clinical trials: Histological Response
Malignant Melanoma
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer…
- Trial name
- NCT01288963
- Testing
- IL-2
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Beth Israel Deaconess Medical Center
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Resectable Esophageal Cancer
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal cancer (EC).
- Trial name
- NCT04006041
- Testing
- Toripalimab, Paclitaxel/cisplatin, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Jianhua Fu
Head and Neck Squamous Cell Carcinoma
Window Trial 5-aza in HNSCC, T-tare
The purpose of this study is to assess the activity of 5-azacitidine in patients with Human Papilloma Virus (HPV)-positive and HPV- negative head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT02178072
- Testing
- 5-Azacitadine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Invasive Ductal Carcinoma, Breast
Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer
This study will investigate the safety, feasibility, and immune response associated with cryoablation of early invasive breast cancer prior to lumpectomy.
- Trial name
- NCT03523299
- Testing
- Cryoablation
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cutaneous Neurofibroma, Neurofibromatosis 1
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
This is a randomized, double-blind, vehicle-controlled, parallel group dose response study evaluating the safety and effectiveness of 2 concentrations of NFX-179 gel in participants with cNF.
- Trial name
- NCT05005845
- Testing
- NFX-179 gel, Vehicle gel
- Where
- 23 sites in United States
- Volunteers
- 199 people
- Sponsor
- NFlection Therapeutics, Inc.
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will improve long-term…
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
- Trial name
- NCT00096460
- Testing
- Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy
- Where
- 30 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Carcinoma, Squamous Cell
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
This is an open label, Phase 1b pre-operative window of opportunity biomarker trial to analyze the combination of intravenous (IV) anti-PD-1 inhibitor, nivolumab, given along with toll-like receptor 8 (TLR 8) agonist motolimod…
- Trial name
- NCT03906526
- Testing
- VTX-2337, Nivolumab
- Where
- 12 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celgene
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
The purpose of this study is to determine whether deferasirox is effective in the treatment of acute lymphatic leukemia (ALL) and acute Myeloid leukemia (AML).
- Trial name
- NCT02413021
- Testing
- Cytarabine, Deferasirox
- Volunteers
- 40 people
- Sponsor
- Isfahan University of Medical Sciences
Hepatocellular Carcinoma
Efficacy of Radiation Therapy and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma (HCC)
In this study, the investigators are to prospectively evaluate patient's survival, tumor response, and safety of RT followed by TACE in Child A patients with unilobar portal vein invasion.
- Trial name
- RTANDTACE (NCT01432314)
- Testing
- Radiation therapy, Transarterial chemoembolization
- Sponsor
- Asan Medical Center
NeuroEndocrine Tumours
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Circulating tumour cells (CTCs) are detectable in the blood in around 50% of patients with functioning NeuroEndocrine Tumours (NET) arising in the midgut area (tumours which are secreting hormones and are located in the area in…
- Trial name
- CALM-NET (NCT02075606)
- Testing
- lanreotide acetate
- Where
- 14 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Ipsen
Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
This study will evaluate a gene expression signature (Growth Factor Signature [GFS]) as a biomarker for response/resistance to BRC-ABL oncogene inhibitors.
- Trial name
- NCT00860535
- Testing
- Comparator: Biomarker evaluation
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Neoplasms, Hepatic Cirrhosis
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
There is a high prevalence of hepatic cirrhosis in patients with hepatocellular carcinomas (HCC), or chemotherapy-induced hepatic atrophy or hepatosteatosis in patients with liver metastases associated with high risk of…
- Conditions
- Liver Neoplasms, Hepatic Cirrhosis, Hepatic Carcinoma, Liver Cancer
- Trial name
- NCT04682847
- Testing
- Ferumoxytol injection
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer
Clinically, there has been extensive experience with topotecan and cisplatin. Recently, several investigators have evaluated the combination of paclitaxel, cisplatin and topotecan.
- Trial name
- NCT00314678
- Testing
- Topotecan, Cisplatin, Paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- John P. Fruehauf
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
The aim of this study is to support development of asciminib in the pediatric population (1 to < 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose…
- Trial name
- NCT07354074
- Testing
- Asciminib single agent
- Where
- 34 sites in United States, Australia and 13 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Epithelial Ovarian Cancer
Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer
EXCYTE-1 is a multicentre, prospective observational study to investigate the relationship between ex vivo drug response (EVDR), measured in ovarian tumour-derived samples using high content imaging, and actual patient clinical…
- Trial name
- EXCYTE-1 (NCT06068738)
- Testing
- Biological sample collection
- Where
- 4 sites in Austria, Germany
- Volunteers
- 13 people
- Sponsor
- Exscientia AI Limited
Emergencies, Pediatric ALL
Pediatric Telephone Center Board 15
This study evaluates the follow-up of advices given in a Urgent Medical Aid Service (SAMU 29) for every pediatric's emergency call under 15yo and try to evaluate the adhesion's factors.
- Conditions
- Emergencies, Pediatric ALL, Response, Acute Phase
- Trial name
- CTPC15 (NCT05642117)
- Where
- France
- Volunteers
- 785 people
- Sponsor
- University Hospital, Brest
Renal Cell Carcinoma
Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma
Magnetic Resonance Imaging (MRI) including Arterial Spin Labeling (ASL) will be performed before, during, and after the treatment, in a total of up to 6 MRI sessions until 7 months after the first session, or when progression is…
- Trial name
- NCT04831138
- Testing
- MRI with ASL, ASL-MRI
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Neuroendocrine Tumors
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
People with neuroendocrine cancer typically have imaging scans before and after treatment, including positron emission tomography (PET) scans.
- Trial name
- NCT06448208
- Testing
- positron emission tomography (PET) scans
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myelogenous Leukemia
Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
The purpose of this study is to assess whether treatment with cenersen in combination with 4 cycles of high and low-dose chemotherapy (idarubicin and cytarabine) improves the complete response rate in acute myelogenous leukemia…
- Trial name
- NCT00967512
- Testing
- cenersen, idarubicin, cytarabine
- Sponsor
- Eleos, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.